-
Atopic Dermatitis Market to Register Incremental Growth by 2034, Examines DelveInsight | Key Companies - Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant Sciences, Cara Therapeutics, Pfizer, Arena Pharmaceuticals
02 Jul 2024 17:00 GMT
… Sciences, Cara Therapeutics, Pfizer, Arena Pharmaceuticals, BioMimetix, Eli Lilly and … topical corticosteroids (TCS) with antibiotics, topical calcineurin inhibitors (TCIs), … short. Additionally, antistaphylococcal antibiotics are useful for treating …
-
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
04 Jun 2020 12:53 GMT
… 52-week Highs June 3)
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)
BioMarin Pharmaceutical … ) sNDA for its triple combo antibiotic Recarbrio.
Related Link: Attention Biotech …
-
Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight
16 Apr 2025 00:29 GMT
… -104, a combination macrolide antibiotic, is in Phase III trials … Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, … Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, …
-
Crohn's Disease Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA Approvals by DelveInsight
13 Jan 2025 12:53 GMT
… Drug treatments include aminosalicylates, antibiotics, and corticosteroids for initial … Eli Lilly and Company, Arena Pharmaceuticals, RedHill Biopharma, Janssen, … VELSIPITY (etrasimod): Pfizer/Arena Pharmaceuticals
Zeposia (Ozanimod; RPC1063): Celgene …